Ohio Medicaid does not cover Wegovy when it is prescribed for weight loss. As of early 2026, the program does cover Wegovy in two narrow situations: to reduce cardiovascular risk in certain adults with existing heart disease, and to treat a serious form of fatty liver disease called MASH. Both require prior authorization, and neither pathway is open to patients with diabetes.1Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
Why Weight-Loss Coverage Is Blocked
The exclusion is written into Ohio Administrative Code Rule 5160-9-03, which lists “drugs for the treatment of obesity” as non-covered. The same rule makes those drugs ineligible for prior authorization, so a prescriber cannot request an exception through the normal approval channel.2Ohio Legislative Service Commission. Rule 5160-9-03 Coverage of Drugs
The exclusion applies across the whole Ohio Medicaid system. Whether an enrollee has traditional fee-for-service coverage or a managed care plan such as CareSource, Molina, UnitedHealthcare, Buckeye, or AmeriHealth Caritas, the same Unified Preferred Drug List governs pharmacy benefits, and the state’s single pharmacy benefit manager handbook specifically lists obesity drugs as an excluded service.3Ohio Department of Medicaid. SPBM Member Handbook Federal law lets states exclude weight-loss drugs from Medicaid, and Ohio has done so.4KFF. Medicaid Coverage of and Spending on GLP-1s
When Wegovy Is Covered: The Cardiovascular and MASH Exceptions
In January 2026, Ohio Medicaid’s Pharmacy and Therapeutics Committee created a new drug class, “Metabolic Modifiers: GLP-1 Receptor Agonists for Non-Obesity Indications.” Wegovy is listed as preferred in that class, with clinical prior authorization required, for two conditions only.1Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
Cardiovascular Risk Reduction
To qualify under this pathway, a patient must be at least 18, have a BMI of 27 or higher, have documented atherosclerotic cardiovascular disease (such as a prior heart attack, prior stroke, or symptomatic peripheral artery disease), and already be taking standard cardiovascular medications. Patients with type 1 or type 2 diabetes are excluded from this pathway.1Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
MASH (Metabolic Dysfunction-Associated Steatohepatitis)
The second pathway covers Wegovy for MASH, a serious form of fatty liver disease. The patient must be 18 or older, non-diabetic, and have confirmed moderate to advanced liver fibrosis. That confirmation comes from either a liver biopsy within the past 24 months or a combination of diagnostic tests. The patient must also be following a reduced-calorie diet and a physical activity program.1Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
Authorization Length and Renewal
Approvals under either pathway last 180 days. To renew, the patient has to show at least five percent weight loss from baseline and at least 80 percent medication adherence based on pharmacy claims.1Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
GLP-1 Coverage for Type 2 Diabetes Is Different
If the prescription is for type 2 diabetes rather than weight loss, GLP-1 coverage is available, but not through Wegovy. Ozempic is on the state’s preferred formulary with prior authorization. Mounjaro (tirzepatide) is also available, but the state requires the patient to try Ozempic first or document why they cannot use it; qualifying for Mounjaro requires a hemoglobin A1C above seven percent and an inadequate response after at least 120 days on Ozempic.5Ohio Department of Medicaid. Unified Preferred Drug List Changes, Effective January 1, 2026
Obesity Treatments Ohio Medicaid Does Cover
For enrollees who need help with obesity but cannot get medication coverage, some non-drug options are available. A 2024 analysis by the GWU STOP Obesity Alliance found that Ohio Medicaid covers nutrition counseling and provides intensive behavioral therapy with some limits (the services are not obesity-specific). Metabolic and bariatric surgery is covered with restrictions.6GWU STOP Obesity Alliance. Ohio State Snapshot, Medicaid Obesity Coverage 2024
What Could Change Coverage
Several efforts are in motion, but none has changed the exclusion. At the state level, House Bill 388, introduced by Representatives Josh Williams and Dontavius Jarrells, would create a reimbursement model for state employees rather than Medicaid enrollees. As of mid-2026, the bill remains in the House General Government Committee.7Ohio General Assembly. House Bill 388
Advocacy groups have pressed for a direct change to the administrative rule. The Alliance for Women’s Health and Prevention has called for removing the obesity-drug prohibition from Ohio Administrative Code Section 5160-9-03.8Alliance for Women’s Health and Prevention. Urging Removal of the Prohibition on Medicaid Coverage for Obesity Medications An April 2026 op-ed in the Columbus Dispatch by the president of Ohio Life Sciences argued that the governor has authority to remove the prohibition without legislative approval.9The Columbus Dispatch. Ohio Medicaid Obesity Drugs GLP-1 Opinion Absent that kind of action, the rule is not scheduled for its next routine five-year review until February 2029.2Ohio Legislative Service Commission. Rule 5160-9-03 Coverage of Drugs
At the federal level, a proposed rule (CMS-4208-P) that would have required state Medicaid programs to cover anti-obesity medications was not finalized. The final rule released in April 2025 omitted the mandate, with CMS saying only that it “reserves the right to include provisions in future rulemaking.”10CMS. Contract Year 2026 Policy and Technical Changes Final Rule Fact Sheet CMS also launched the voluntary BALANCE model in December 2025, a five-year program that negotiates lower GLP-1 prices with manufacturers to encourage states to expand access. State Medicaid agencies can apply beginning in May 2026, and the available records do not indicate whether Ohio plans to join.11CMS. BALANCE Model
Appealing a Wegovy Denial
Because the weight-loss exclusion is a blanket policy, an appeal of a Wegovy denial for weight loss is unlikely to succeed. Appeals are more useful when the prescription arguably fits one of the covered indications (cardiovascular risk reduction or MASH) and the denial rests on how those criteria were applied.
For managed care enrollees, the first step is an internal appeal with the plan, filed within 60 days of the denial notice. The plan has 15 days to resolve a standard appeal. An expedited appeal, for urgent situations, must be resolved within 72 hours. To keep receiving current benefits during the appeal, file within 15 days of the denial.12Disability Rights Ohio. Medicaid Appeals Overview
If the plan upholds the denial, the next step is a state hearing through the Ohio Department of Job and Family Services Bureau of State Hearings. That request must be filed within 120 days of the plan’s appeal resolution and can be submitted by mail, fax, email, online, or phone. Decisions are typically issued within 70 days.12Disability Rights Ohio. Medicaid Appeals Overview For legal help, Ohio Legal Help can be reached at 866-529-6446 and Disability Rights Ohio at 800-282-9181.13Ohio Medicaid Health. Appeals